[18F]Fluorodeoxyglucose positron emission tomography and its prognostic value in lung cancer

European Journal of Cardio-thoracic Surgery

Volumn 18, Issue 4, 2000, Pages 425-428

  Dhital, Kumud ^a   Saunders, Catherine A B ^a   Seed, Paul T ^a   O'Doherty, Michael J ^a   Dussek, Julian ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Lung neoplasm; Positron emission tomography; Prognosis; Surgery

Indexed keywords

FLUORODEOXYGLUCOSE F 18; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ARTICLE; CANCER STAGING; CLINICAL TRIAL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HISTOLOGY; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; SURVIVAL; TREATMENT OUTCOME; LUNG TUMOR; MIDDLE AGED; MORTALITY; SCINTISCANNING;

ADULT; AGED; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0034287440     PISSN: 10107940     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1010-7940(00)00535-2     Document Type: Article

References (15)

1. Lowe V.J., Naunheim K.S. Current role of positron emission tomography in thoracic oncology. Thorax. 53:1998;703-712.
2. Saunders C.A.B., Dussek J., O'Doherty M.J., Maisey M.N. An evaluation of 18F-FDG whole body PET imaging in the staging of lung cancer. Ann Thorac Surg. 67:1999;790-797.
3. 18F]-2-deoxy-2-fluoro-D-glucose. J Nucl Med. 19:1978;1154-1161.
4. Minn H., Zasadny K.R., Quint C.E., Wahl R.L. Lung cancer: reproducibility of quantitative measurements for evaluating 2-[F-18]-fluoro-2-deoxy-D-glucose uptake at PET. Radiology. 196:1995;167-173.
5. Duhaylongsod F.G., Lowe V.J., Patz E.F., Vaughan A.L., Coleman R.E., Wolfe W.G. Lung tumour growth correlates with glucose metabolism measured by fluoride-18-fluorodeoxyglucose positron emission tomography. Ann Thorac Surg. 60:1995;1348-1352.
6. Ahuja V., Coleman R.E., Herndon J., Patz E.F. The prognostic significance of fluorodeoxyglucose positron emission tomography imaging for patients with non-small cell lung carcinoma. Cancer. 83:1998;918-924.
7. Zasadny K.R., Wahl R.L. Standardized uptake values of normal tissues at PET with 2-[fluorine-18]-fluoro-2-deoxy-D-glucose: variations with body weight and a method for correction. Radiology. 189:1993;847-850.
8. McLoud T.C., Bourgouin P.M., Greenberg R.W., Kosiuk J.P. Bronchogenic carcinoma: analysis of staging in the mediastinum with CT by correlative lymph nodemapping and sampling. Radiology. 182:1992;319-323.
9. Wahl R.L., Quint L.E., Greenough R.L., Meyer C.R., White R.I., Orringer M.B. Staging of mediastinal non-small cell lung cancer with FDG PET, CT, and fusion images: preliminary prospective evaluation. Radiology. 191:1994;371-377.
10. Dewan N.A., Reeb S.D., Gupta N.C., Gobar L.S., Scott J.J. PET-FDG imaging and transthoracic needle lung aspiration biopsy in evaluation of pulmonary lesions. A comparative risk-benefit analysis. Chest. 108:1995;441-446.
11. Scott W.J., Gobar L.S., Terry J.D., Dewan N.A., Sunderland J.J. Mediastinal lymph node staging of non-small cell lung cancer: a prospective comparison of computed tomography and positron emission tomography. J Thorac Cardiovasc Surg. 111:1996;642-646.
12. Steinert H.C., Hauser M., Alleman F., Engel F., Berthold T., von Shulthess G.K., Weder W. Non-small cell lung cancer: nodal staging with FDG-PET versus CT with correlative lymph node mapping and sampling. Radiology. 202:1997;441-446.
13. Gupta N.C., Graeber G.M., Rogers J.S., Bishop H.A. Comparative efficacy of positron emission tomography with FDG and computed tomographic scanning in preoperative staging of non-small cell lung cancer. Ann Surg. 229:1999;286-291.
14. Lowe V.J., Naunheim K.S. Positron emission tomography in lung cancer. Ann Thorac Surg. 65:1998;1821-1829.
15. Scott W.J., Shepherd J., Gambhir S.S. Cost-effectiveness of FDG for staging non-small cell lung cancer: a decision analysis. Ann Thorac Surg. 66:1998;1876-1883.